Dr. Escalon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1611 Nw 12th Ave
Box 016960 M851
Miami, FL 33136Phone+1 305-585-1111
Education & Training
Imperial CollegeExecutive MBA, 2014
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2002 - 2005- University of Texas Medical School at Houston - Ruiz Dept of Ophthalmology & Visual ScienceMSc, Clinical Research, emphasis on Immunology, 2005
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1999 - 2002
University of Florida College of MedicineClass of 1999- Florida State UniversityBS, Biochemistry, 1995
Certifications & Licensure
FL State Medical License 2001 - 2026
AZ State Medical License 2019 - 2025
NC State Medical License 2018 - 2022
TX State Medical License 2002 - 2005
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
- Fellow of the Year Award MD Anderson
- Young Investigator Award American Society of Clinical Oncology
- Join now to see all
Clinical Trials
- Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma Start of enrollment: 2007 Feb 01
Publications & Presentations
PubMed
- 129 citationsSirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease.Daniel R. Couriel, Rima M. Saliba, Maricer P. Escalon, Yvonne Hsu, S. Ghosh
British Journal of Haematology. 2005-08-01 - 47 citationsEUS-guided biopsy for the diagnosis and classification of lymphomaAfonso Ribeiro, Denise Pereira, Maricer P. Escalón, Mark Goodman, Gerald E. Byrne
Gastrointestinal Endoscopy. 2010-04-01 - 175 citationsPrognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.Maricer P. Escalón, Nina S. Liu, Ying Yang, B A Mark Hess, L R N Pamela Walker
Cancer. 2005-05-15
Press Mentions
Ensysce Biosciences Receives Investigational New Drug Allowance for Its Unique PF614-MPAR™ Opioid with Overdose ProtectionApril 29th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
